Alnylam Pharmaceuticals, Inc.
- ALNY
- NASDAQ
- Biotechnology
- RNAi Therapeutics
- Genetic Medicines
$233.29
Today +0.63%Quote Oct 19, 2026, 08:00 PM UTC
−5.57%over the last month
Max drawdown −14.2%From 1-month high −9.4%3 months −15.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology.
Where the money comes from
Q2 2026 revenue $1.28B
- Product$1.17B91.5%
- GIVLAARI$89.8M7.0%
- ONPATTRO$18.5M1.4%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
2,500
Market value
$31.22B
Quote Oct 19
Floor
$227.03
2.7% below price
Resistance
$232.55
Price is above this level
Price vs analyst targets
52 analysts
Lowest target
$253.00Highest target
$455.00
$253.00Highest target
$455.00
- Price $233.29
- Average target $347.23
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 49% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALNYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free